MA40783A - Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population - Google Patents

Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population

Info

Publication number
MA40783A
MA40783A MA040783A MA40783A MA40783A MA 40783 A MA40783 A MA 40783A MA 040783 A MA040783 A MA 040783A MA 40783 A MA40783 A MA 40783A MA 40783 A MA40783 A MA 40783A
Authority
MA
Morocco
Prior art keywords
vaccines containing
hiv vaccines
population episensus
episensus antigens
antigens
Prior art date
Application number
MA040783A
Other languages
English (en)
Inventor
Eric Bruening
Klaus Frueh
Bette T M Korber
Emily Marshall
Louis Picker
James Theiler
Original Assignee
Los Alamos Nat Security Llc
Univ Oregon Health & Science
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Alamos Nat Security Llc, Univ Oregon Health & Science, Vir Biotechnology Inc filed Critical Los Alamos Nat Security Llc
Publication of MA40783A publication Critical patent/MA40783A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA040783A 2014-10-03 2015-10-04 Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population MA40783A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059506P 2014-10-03 2014-10-03
US201462059497P 2014-10-03 2014-10-03

Publications (1)

Publication Number Publication Date
MA40783A true MA40783A (fr) 2017-08-08

Family

ID=55631703

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040783A MA40783A (fr) 2014-10-03 2015-10-04 Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population

Country Status (16)

Country Link
US (3) US10894078B2 (fr)
EP (1) EP3200878B1 (fr)
JP (3) JP2017531693A (fr)
KR (1) KR102633096B1 (fr)
CN (1) CN108064181A (fr)
AU (2) AU2015327797A1 (fr)
CA (1) CA2963573C (fr)
EA (1) EA201790680A1 (fr)
HK (1) HK1254806A1 (fr)
IL (1) IL251469B2 (fr)
MA (1) MA40783A (fr)
MX (3) MX391149B (fr)
SG (1) SG11201702729YA (fr)
UA (1) UA126890C2 (fr)
WO (1) WO2016054654A1 (fr)
ZA (1) ZA202206809B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007994A1 (fr) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Pré-immunisation et immunothérapie du vih
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
EP3481418A4 (fr) 2016-07-08 2020-03-11 American Gene Technologies International Inc. Pré-immunisation et immunothérapie du vih
WO2020243485A1 (fr) * 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Compositions immunogènes spécifiques du vih-1 et méthodes d'utilisation
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
MX2022002270A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.
EP4277652A1 (fr) * 2021-01-14 2023-11-22 Gilead Sciences, Inc. Vaccins contre le vih et méthodes d'utilisation
TW202311531A (zh) 2021-08-31 2023-03-16 美商維爾生物科技股份有限公司 重組hcmv載體及其用途
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994B (zh) * 2023-02-20 2026-01-30 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
WO2005012502A2 (fr) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Procedes d'identification de variants optimaux d'epitopes peptidiques
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
SG146662A1 (en) 2003-10-10 2008-10-30 Powderject Vaccines Inc Method
EP2497831B1 (fr) 2004-05-25 2014-07-16 Oregon Health and Science University Vaccin contre la Tuberculosis utilisant des vecteurs de vaccin à base de HCMV
AU2006283101B2 (en) * 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
CA3184778A1 (fr) 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Sequences d'enveloppes de consensus du vih et methodes d'utilisation
WO2008118497A1 (fr) * 2007-03-27 2008-10-02 President And Fellows Of Harvard College Vecteurs du genre rhadinovirus pour l'expression d'un antigène du virus de l'immunodéficience
EP2143035A4 (fr) * 2007-03-30 2013-01-02 Merck Sharp & Dohme Séquences d'antigènes largement représentatifs et leur procédé de sélection
NZ593598A (en) * 2008-11-18 2013-02-22 Beth Israel Hospital Optimized antiviral vaccines with improved cellular immunogenicity
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
EP3333265B1 (fr) * 2010-05-14 2020-02-05 Oregon Health & Science University Vecteurs hcmv et rhcmv recombinants qui encodent un antigène hétérologue du virus de l'hepatite b et leurs utilisations
US8557787B2 (en) * 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2620446A1 (fr) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
EP2820035B1 (fr) 2012-03-02 2019-01-09 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Procédé pour modifier la hiérarchie d'immunodominance du gag de vih par vaccin d'adn exprimant des régions à conservation
AP2015008634A0 (en) 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
SI2964769T1 (sl) 2013-03-05 2018-12-31 Oregon Health & Sccience University Citomegalovirusni vektorji, ki omogočajo krmiljenje ciljanja T-celic
EP3110953A1 (fr) 2014-02-28 2017-01-04 Janssen Vaccines & Prevention B.V. Vecteurs adénoviaux recombinés se répliquant, compositions et procédés pour les utiliser
KR102205348B1 (ko) 2014-07-16 2021-01-20 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
HUE053585T2 (hu) 2014-09-26 2021-07-28 Beth Israel Deaconess Medical Ct Inc Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
PL3390430T3 (pl) 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania

Also Published As

Publication number Publication date
EA201790680A1 (ru) 2017-11-30
UA126890C2 (uk) 2023-02-22
HK1254806A1 (zh) 2019-07-26
JP2021035946A (ja) 2021-03-04
IL251469A0 (en) 2017-05-29
JP7212020B2 (ja) 2023-01-24
NZ731173A (en) 2024-04-26
JP7441340B2 (ja) 2024-03-06
US20210046175A1 (en) 2021-02-18
CA2963573C (fr) 2024-02-06
JP2017531693A (ja) 2017-10-26
BR112017006865A2 (pt) 2017-12-12
MX2017004275A (es) 2018-01-17
KR102633096B1 (ko) 2024-02-02
KR20170122711A (ko) 2017-11-06
WO2016054654A1 (fr) 2016-04-07
US11554168B2 (en) 2023-01-17
MX391149B (es) 2025-03-21
US20170319679A1 (en) 2017-11-09
ZA202206809B (en) 2023-11-29
AU2015327797A1 (en) 2017-05-11
EP3200878B1 (fr) 2025-06-04
EP3200878A4 (fr) 2018-05-30
US11628215B2 (en) 2023-04-18
IL251469B2 (en) 2023-05-01
MX2022003664A (es) 2022-04-25
US10894078B2 (en) 2021-01-19
AU2021218141B2 (en) 2024-06-06
CA2963573A1 (fr) 2016-04-07
EP3200878A1 (fr) 2017-08-09
MX2022003663A (es) 2022-04-25
IL251469B1 (en) 2023-01-01
US20210046174A1 (en) 2021-02-18
SG11201702729YA (en) 2017-04-27
JP2023059272A (ja) 2023-04-26
AU2021218141A1 (en) 2021-09-09
CN108064181A (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
EP3364949A4 (fr) Vaccins anticancéreux
DK3134131T3 (en) Nucleic acid vaccines
EP3413926A4 (fr) Vaccination et immunothérapie contre le vih
IL251469A0 (en) Vaccines for the AIDS virus containing antigens of one or more of the Apisenses population
IL263624B (en) HIV vaccine formulation
IL268570B (en) Oligonucleotide compositions and methods of making the same
IL266237A (en) Tolerogenic DNA composition
PL3110439T3 (pl) Szczepionki PCSK9
EP3528843A4 (fr) Vaccins anti-opioïdes
EP3500280A4 (fr) Vaccins contre des virus
GB201616904D0 (en) Vaccine
GB201615427D0 (en) Francisella glycoconjugate vaccines
GB201603029D0 (en) Vaccine
PT3534936T (pt) Vacina de adn tolerogénica
GB201614387D0 (en) Improved vaccines
GB201408819D0 (en) Antigen immunogenicity characteristion assay
HK1235003A1 (zh) 核酸疫苗
ES1126005Y (es) Envoltorio paza taza